Research / FLEX / Fundamental state Inspectable configuration
State dimensions Filing 0000866374-26-000042 General Corporate
Debt relative to revenue 85th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.debt_to_revenue
61.39% · OPTIONAL · VALID
Capex intensity 95th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
2.84% · OPTIONAL · VALID
Operating cash generation 75th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
5.90% · OPTIONAL · VALID
Revenue growth 100th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
24.79% · CORE · VALID
Inventory pressure 60th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
86.24% · OPTIONAL · VALID
Gross margin 95th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
9.56% · CORE · VALID
Operating margin 70th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
4.88% · CORE · VALID
SBC intensity 50th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.51% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 18 states Self-history eligible
Mar 31, 2019 0/7 normalized Level 3 Mar 31, 2020 0/7 normalized Level 3 Jun 26, 2020 0/7 normalized Level 3 Sep 25, 2020 0/7 normalized Level 3 Dec 31, 2020 6/7 normalized Level 3 Mar 31, 2021 6/7 normalized Level 3 Jul 2, 2021 6/7 normalized Level 3 Oct 1, 2021 6/8 normalized Level 3 Dec 31, 2021 7/8 normalized Level 3 Mar 31, 2022 7/8 normalized Level 3 Jul 1, 2022 7/8 normalized Level 3 Sep 30, 2022 7/8 normalized Level 3 Dec 31, 2022 7/8 normalized Level 3 Mar 31, 2023 7/8 normalized Level 3 Jun 30, 2023 7/8 normalized Level 3 Sep 29, 2023 8/8 normalized Level 3 Dec 31, 2023 8/8 normalized Level 3 Sep 25, 2026 8/8 normalized Level 4 Period transition
What moved in the state? Balance Sheet Leverage Decreased
Previous 65.83%
Current 61.39%
Delta -4.44% Capex Intensity Decreased
Previous 2.98%
Current 2.84%
Delta -0.14% Cash Generation Increased
Previous 3.48%
Current 5.90%
Delta 2.42% Growth Increased
Previous 20.58%
Current 24.79%
Delta 4.22% Inventory Pressure Increased
Previous 81.39%
Current 86.24%
Delta 4.85% Margin Increased
Previous 9.42%
Current 9.56%
Delta 0.14% Profitability Decreased
Previous 4.94%
Current 4.88%
Delta -0.07% Sbc Intensity Decreased
Previous 0.64%
Current 0.51%
Delta -0.14% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Dec 31, 2025
Similarity 80%
Compared 8 dimensions
Coverage 100% Growth 30.0 · Margin 5.0 · Profitability 30.0 · Sbc Intensity 25.0 · Capex Intensity 10.0 · Cash Generation 10.0 · Inventory Pressure 20.0 · Balance Sheet Leverage 10.0 Jun 27, 2025
Similarity 78%
Compared 8 dimensions
Coverage 100% Growth 30.0 · Margin 10.0 · Profitability 10.0 · Sbc Intensity 30.0 · Capex Intensity 25.0 · Cash Generation 20.0 · Inventory Pressure 15.0 · Balance Sheet Leverage 25.0 Sep 30, 2022
Similarity 77%
Compared 7 dimensions
Coverage 88% Growth 0.0 · Margin 5.0 · Sbc Intensity 10.0 · Capex Intensity 8.3 · Cash Generation 21.7 · Inventory Pressure 40.0 · Balance Sheet Leverage 38.3 Jun 26, 2026
Similarity 75%
Compared 8 dimensions
Coverage 100% Growth 10.0 · Margin 0.0 · Profitability 14.2 · Sbc Intensity 50.0 · Capex Intensity 5.0 · Cash Generation 45.0 · Inventory Pressure 10.0 · Balance Sheet Leverage 10.0 Jul 2, 2021
Similarity 73%
Compared 6 dimensions
Coverage 75% Margin 5.0 · Sbc Intensity 10.0 · Capex Intensity 45.0 · Cash Generation 25.0 · Inventory Pressure 40.0 · Balance Sheet Leverage 5.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.